Michelle joined HGF Law as Legal Director in March 2017 and is a highly experienced solicitor and transactional IP specialist.
Michelle provides strategic and transactional IP advice to clients in a wide range of sectors but has specific expertise within the Pharmaceutical and Life Sciences Sector having worked 11+ years with AstraZeneca and with a BSc in Pharmacology & Physiology.
Michelle is well attuned to the requirements and complexities of IP protection in pharmaceutical development, having drafted, negotiated and advised on a whole range of development, clinical, manufacturing, services and supply contracts, not only in the context of product development but also involving devices, testing kits, biomarkers and biologic models.
Michelle has provided IP advice on a number of major corporate licensing transactions, acquisitions and business sales and works regularly with many educational institutions and their spin-out companies.
In addition to her expertise in the life sciences sector, Michelle also advises clients within the retail sector in connection with brand licensing, digital content arrangements, data privacy, website development, commercial terms of business, distribution and supply.
Michelle regularly presents on a broad range of IP and commercial topics including licensing, strategic IP protection, GDPR and during 2017/18 rolled out a number of training sessions on the contractual implications under the proposed UP/UPC system including to CIPA, Imperial Innovations, AstraZeneca, Hewlitt Packard and Syngenta.